iPSC-derived cell products

iPSC-derived Human Hepatic Stellate cells

Introducing the first commercially available iPSC-derived human hepatic stellate cells ready for large-scale screening of antifibrotic drugs. Unlike primary cells, our hepatic stellate cells are derived from a single donor, ensuring no donor-to-donor variation and providing researchers with reproducible results. Our cells are scalable, unlike primary cells, so that we can meet your needs, facilitating more efficient and effective drug discovery whilst reducing the need for animal models.

iPSC-derived Human Hepatocytes: Wilson's Disease

DefiniGEN's iPSC-derived Wilson's Disease (WD) hepatocytes provide a relevant disease modeling platform to study this rare disease.  

Cells are generated through CRISPR engineering and carry the homozygous H1069Q mutation in the ATP7B gene. This mutation causes a decrease in the protein function and leads to excessive accumulation of copper that can cause damage to the liver, brain, and other vital organs. DefiniGEN's iPSC-dervied WD hepatocytes are a powerful tool for drug discovery applications and can help investigate this monogenic disease and other conditions related to oxidative stress. 

 iPSC-derived Human Hepatocytes:                  Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is characterized by the accumulation of fat within the liver that can lead to inflammation, fibrosis, and hepatocellular carcinoma. Although it's not a monogenic disease, several variants have been associated with increased risk to develop MASLD.

DefiniGEN's iPSC-derived MASLD hepatocytes have been edited to include some of the most common genetic variants implicated in the disease. One of the lines includes the missense homozygous mutation I148M in the gene coding for Patatin-like phospholipase domain-containing protein 3 (PNPLA3) and another line harbors the homozgyous E167K mutation in the gene encoding for Transmembrane 6 Superfamily Member 2 (TM6SF2).

DefiniGEN's iPSC-derived MASLD hepatocytes are an important tool for disease modeling and drug discovery for this common liver disease. 

iPSC-derived Human Hepatocytes: Alpha-1 Antitrypsin Deficiency

DefiniGEN provides iPSC-derived Alpha-1 Antitrypsin deficiency (A1ATD) hepatocytes which are highly functional and showcase a strong diseased phenotype in vitro.

Cells are derived from either A1ATD patients or generated through CRISPR engineering and carry the 'Z' (E342K) point mutation in the SERPINA1 gene. This mutation leads to the accumulation of polymeric aggregates of the proteins that ultimately cause liver and lung damage. DefiniGEN's iPSC-derived A1ATD hepatocytes represent an optimized disease model for drug discovery applications and are an effective tool for elucidating the underlying mechanisms of the disease.

DefiniGEN offer homozygous patient-derived A1AT cells and both homozygous and heterozygous CRISPR-engineered A1ATD lines.

iPSC-derived Human Intestinal Organoids: Wild-Type

DefiniGEN's iPSC-derived Wild-Type (WT) intestinal organoids provide a unique in vitro system to model the human intestine. The organoids display a polarized epithelium and harbor a mixture of cell types normally present in the primary intestinal epithelial barrier in vivo, including goblet cells, Paneth cells, enterocytes, and enteroendocrine cells. The cells can be used for drug absorption, metabolism, and the modeling of infectious disease.

DefiniGEN's intestinal monolayer constitutes an effective application to model the permeability of the human intestine and investigate drug absorption and metabolism. Following a simple and standardized protocol, cells from DefiniGEN's intestinal organoids can be grown as a monolayer in a similar manner to standard Caco-2 immortalized cell lines with the key benefit of greatly increased biological relevance, as the cells have primary human intestinal cell function, metabolism and genetics.